• Français Français French fr
  • English English English en
Medicalps
  • MEDICALPS
    • Who we are
    • Governance and team
  • Healthcare in Isère
  • News
  • Contact us
  • Search
  • Menu Menu

Members directory

UROMEMS is an innovative company focuses on designing, developing and commercializing active implantable medical devices for the severe urinary incontinence treatment. Company’s ambition is to improve current surgical treatments for helping as many patients as possible, particularly by reducing associated side effects and difficulties faced by healthcare professionals.

 

UROMEMS’s mission is to offer implantable solutions that are :

– easy to use for the patient in order to give them back a real autonomy and a normal social life,

– easy to operate for healthcare professionals,

– more effective, less invasive than current surgical techniques.

 

Company’s ambition is to revolutionize the treatment for severe urinary incontinence using the latest technological advances in the field of embedded systems and micro-technologies for the development of its implantable products

UROMEMS

32 rue Gustave Eiffel
38000 GRENOBLE - FRANCE

Date of creation : 2011

Number of employees : 11

www.uromems.com

Director

Hamid LAMRAOUI

+33 (0)4 80 42 02 41

hamid.lamraoui@uromems.com

Contact

Myriam LECLERC

+33 (0)4 80 42 02 40

myriam.leclerc@uromems.com

Uromems
Evènements

UroMems Raises €16 Million to Advance Development of Electronic Artificial Urinary Sphincter (eAUS) for Stress Urinary Incontinence

0 Commentaires
/
20 May 2020
Lire la suite →
Evènements

UROMEMS closes €14M financing to develop its smart artificial urinary sphincter to market

0 Commentaires
/
15 November 2016
Lire la suite →
Back to the members list

FOLLOW US !


  • Twitter
  • Linkedin
  • YouTube

NEWS

  • BIOTEM implements new industrial unit dedicated to development and production of immunoassays
  • As SYNTHELIS and PEACCEL have signed a strategic partnership to offer their clients a one-stop shop combining Artificial Intelligence (AI) and Cell-Free lead expression for accelerated drug discovery
  • Microlight 3D releases new range of resins for 3D microprinting

Subscribe to receive the newsletter

By clicking on "Subscribe", You agree to receive the MEDICALPS newsletter and offers every month.
You can easily unsubscribe at any time via the unsubscribe link in each of our emails.

MEDICALPS

5, avenue du Grand Sablon
38700 La Tronche
France

Tel. +33 (0)4 76 54 95 63

  • © 2016 – Medicalps
  • Sitemap
  • Legal
VÊPRES UGA
Scroll to top